Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

Anagnostis, Panagiotis; Paschou, Stavroula; Mintziori, Gesthimani; Ceausu, Iuliana; Depypere, Herman; Lambrinoudaki, Irene; Mueck, Alfred; Perez-Lopez, Faustino; Rees, Margaret; Senturk, Levent; Simoncini, Tommaso; Stevenson, John; Stute, Petra; Tremollieres, Florence; Goulis, Dimitrios

doi:10.1016/j.maturitas.2017.04.008

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

Anagnostis P., Paschou S. A., Mintziori G., Ceausu I., Depypere H., Lambrinoudaki I., ...More

MATURITAS, vol.101, pp.23-30, 2017 (SCI-Expanded, Scopus)

Publication Type: Article / Review
Volume: 101
Publication Date: 2017
Doi Number: 10.1016/j.maturitas.2017.04.008
Journal Name: MATURITAS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.23-30
Open Archive Collection: AVESIS Open Access Collection
Istanbul University-Cerrahpasa Affiliated: No

Abstract

Background: Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal osteoporosis. Despite their proven efficacy in the reduction of vertebral and non-vertebral fractures, their optimal duration of use has not been determined. The occurrence of adverse effects, such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF), has raised the issue of bisphosphonate or denosumab discontinuation ("drug holiday") after a certain treatment period.